A Registry for Patients Treated on the Clinical Trial TAX 3503

Summary

The purpose of this study is to continue follow-up on patients who were treated on the study called TAX 3505 (MSK IRB #07-101). The sponsor of this study, has decided to end the study early, before all patients have completed all planned follow-up tests. As a result, the investigators do not yet know whether hormonal therapy alone, or in combination with docetaxel, is better at preventing prostate cancer recurrence in patients who had a rising PSA after prostatectomy. This study will continue following patients according to a schedule that is similar to that found in the TAX 3503 (MSK IRB #07-101) study in order to answer that question. This study is known as a registry study. The patients' will not receive any treatment as part of this study. Instead, they will be asked to have a blood test performed once every 12 weeks.

Conditions

• Prostate Cancer

Interventions

OTHER

No intervention

No intervention is planned as part of this protocol. Historical data will be transferred to MSK via electronic data transfer. Patient's PSA, testosterone, and vital status data will be transferred to MSK via electronic data transfer.

Sponsors & Collaborators

• Laval University

  collaborator OTHER

• Vancouver General Hospital

  collaborator OTHER

• London Health Sciences Centre

  collaborator OTHER

• Centre Hospitalier Universitaire de Montreal - Hospital Notre-Dame

  collaborator UNKNOWN

• Princess Margaret Hospital, Canada

  collaborator OTHER

• CancerCare Manitoba

  collaborator OTHER

• Tom Baker Cancer Centre

  collaborator OTHER

• Urocentrum Praha s.r.o.

  collaborator UNKNOWN

• Fakultní nemocnice Na Bulovce

  collaborator UNKNOWN

• Hospital Jablonec nad Nisou, p.o

  collaborator UNKNOWN

• Klaipėda University

  collaborator OTHER

• Lithuanian University of Health Sciences

  collaborator OTHER

• Oncology Institute of Vilnius University

  collaborator UNKNOWN

• Fakultna Nemocnica s poliklinikou J.A. Reimana Presov, Klinika urologie

  collaborator UNKNOWN

• Martinska Fakultna Nemocnica, Urologicke klinika

  collaborator UNKNOWN

• Fakultna nemocnica s poliklinikou

  collaborator UNKNOWN

• BratislavaNemocnica ak. L Derera, Urologicka klinika

  collaborator UNKNOWN

• Urologic Consultants of Southeastern PA

  collaborator OTHER

• Columbia University

  collaborator OTHER

• GU Research Network, LLC

  collaborator OTHER

• Carolina Urologic Research Center

  collaborator OTHER

• Lancaster Urology

  collaborator UNKNOWN

• Kansas City Veteran Affairs Medical Center

  collaborator FED

• Urology San Antonio Research PA

  collaborator UNKNOWN

• University of Texas Southwestern Medical Center

  collaborator OTHER

• University of Cincinnati

  collaborator OTHER

• St. Alexius Medical Center Clinical Research Services

  collaborator UNKNOWN

• Barbara Ann Karmanos Cancer Institute

  collaborator OTHER

• Johns Hopkins University

  collaborator OTHER

• Duke University

  collaborator OTHER

• Vanguard Urologic Research Foundation

  collaborator OTHER

• The Urological Institute of Northeastern NY

  collaborator UNKNOWN

• Urology Associates Medical Group

  collaborator UNKNOWN

• Hospital de Sabadell

  collaborator OTHER

• Lahey Clinic

  collaborator OTHER

• San Bernardino Urological Associates

  collaborator UNKNOWN

• Columbus Urology

  collaborator UNKNOWN

• Niepubliczny Specjalistyczny Onkologiczny Zaklad Opienki Zdrowotnej

  collaborator UNKNOWN

• Vinzenzkrankenhaus Hannover, Urologische Abteilung (Uro-Onkologie)

  collaborator UNKNOWN

• Memorial Sloan Kettering Cancer Center

  lead OTHER

Principal Investigators

• Michael Morris, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age

18 Years

Sex

MALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2013-03-31

Primary Completion

2022-03-04

Completion

2022-03-04

Countries

• United States
• Canada
• Lithuania

Study Locations